|
|
||||||||
|
FJ
EXPRESS SUMMARY ARTICLE The Full-length version of this article is also available, published online May 18, 2001 as doi:10.1096/fj.00-0841fje. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institute of Biochemistry and
* Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, BIL Biomedical Research Center, CH-1066 Epalinges, Switzerland
3Correspondence: Institute of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland. E-mail: daniel.legler{at}ib.unil.ch
SPECIFIC AIM
Palmitoylation of Lck, Fyn, LAT, CD4, and CD8 is essential for their partitioning in lipid rafts and functional integrity. We investigate whether an exogenous palmitoyl-phospholipid can interfere with the recruitment of palmitoylated signaling molecules to lipid rafts and thus compromise MHC-peptide-driven CTL activation.
PRINCIPAL FINDINGS
1. DPPE, but not DOPE, partitions in lipid rafts of cloned CTL
As T cells, we used cloned H-2Kd-restricted
S14 CTL, which are specific for a photoreactive derivative of the
Plasmodium berghei circumsporozoite peptide 252260
(SYIPSAEKI), PbCS(ABA). To investigate whether
dipalmitoyl-phosphatidyl-ethanolamine (DPPE), which undergoes extensive
flip-flop from the outer to the inner leaflet of the cell membrane, can
affect antigen-specific CTL activation by interfering with the function
of raft-associated signaling molecules, we first assessed whether DPPE
partitions in lipid rafts. S14 CTL were treated with EITC-labeled DPPE,
lysed in cold Triton X-100, and the fluorescence of
DPPEEITC was measured in the detergent soluble
(membrane, M) and insoluble (lipid rafts, DIG) fractions. As shown in
Fig. 1A
,
34% of DPPE was found in the DIG fraction. A similar
distribution was observed for cholesterol, which is a major constituent
of lipid rafts. By contrast, less than 7% of DOPE, which differs from
DPPE only by having unsaturated oleic acid in place of saturated
palmitic acid, partitioned in DIG.
|
2. DPPE inhibits antigen-mediated CTL activation
Treatment of S14 CTL with DPPE completely abolished
esterase release (Fig. 1B
) and intracellular calcium
mobilization (Fig. 1C
) upon incubation with
PbCS(ABA)-sensitized APC. By contrast, these functions were
barely affected by DOPE treatment of the effector cells. Similar
effects were observed when S14 CTL were incubated with soluble
MHC-peptide tetramers (Kd-PbCS(ABA)-tetramers).
However, DPPE treatment of S14 CTL did not affect their ability to form
conjugates with specific peptide-pulsed syngeneic target cells. In
addition, lipid treatment had no adverse effect on cell viability.
3. DPPE does not affect the integrity of lipid rafts
DPPE-treated S14 CTL were stained with FITC-labeled cholera toxin
B, a reagent that binds to the ganglioside GM1, which is enriched in
lipid rafts. DPPE-treated cells exhibited the same cell surface
staining pattern as untreated or DOPE-treated cells, suggesting that
DPPE insertion into the membrane had no effect on the surface
distribution or expression of GM1. In addition, DPPE treatment did not
alter the ability of lipid rafts to form large clusters on
antibody-mediated cross-linking of GM1-cholera toxin. Similar results
were obtained on cross-linking of the GPI-linked Thy-1 molecule,
another lipid raft constituent, suggesting that DPPE treatment does not
compromise the mobility and integrity of lipid rafts, which play a
crucial role in TCR signaling. DPPE and DOPE had no apparent effect on
the lipid raft localization of CD3
, CD8, Lck, Fyn, or Thy-1.
4. DPPE blocks the recruitment of signaling molecules to lipid
rafts
To define the molecular basis of the inhibitory effect of DPPE, we
compared the distribution of essential signaling molecules in lipid
rafts of DPPE or DOPE-treated and untreated S14 CTL after activation
with Kd-PbCS(ABA)-tetramers. As shown in
Fig. 2A
, this antigen-specific TCR engagement resulted in the
recruitment of substantial amounts of CD3
, CD8, and Lck to lipid
rafts in untreated or DOPE-treated CTL, whereas translocation of these
molecules was strongly reduced in DPPE-treated cells. We demonstrate
that DPPE selectively prevents T cell activation by impairing Src
kinase activity (Fig. 2B
) and activation-induced recruitment
of palmitoylated signaling molecules to lipid rafts.
|
CONCLUSIONS AND SIGNIFICANCE
Plasma membranes of lymphocytes contain microdomains
enriched in sphingolipids and cholesterol, termed lipid rafts.
Acylation of key signaling molecules is essential for their
partitioning in lipid rafts and their contribution to the TCR signaling
process. In resting T cells, the TCR complex is excluded from these
microdomains (Fig. 3
).
|
Studies of Jurkat T cells, thymocytes, and hybridomas indicated that
stimulation of the cells anti-CD3 antibodies induced translocation of
TCR/CD3 and other signaling molecules to lipid rafts. Physiological
antigen-specific activation of T cells, however, is induced by
MHC-peptide complexes on APC. To investigate the early events of TCR
signaling in cloned H-2Kd-restricted CTL, we used
soluble MHC-peptide tetramers, which, unlike anti-CD3 antibodies,
engage not only the TCR complex, but also the coreceptor. Activation
with Kd-PbCS(ABA)-tetramers resulted in TCR
engagement, which causes aggregation of lipid raft-associated proteins
such as the coreceptor CD8, the Src kinases Lck and Fyn, as well as the
adaptor protein LAT. Moreover, lipid raft aggregation promotes tyrosine
phosphorylation and recruitment of downstream signaling molecules. This
activation-induced translocation of signaling molecules to lipid rafts
was strongly reduced in DPPE-treated CTL (Fig. 3)
.
It has recently been reported in a human trial and in in vitro studies that polyunsaturated fatty acids modulate immune responses as a result of inhibition of protein palmitoylation and TCR signaling by modifying the composition of lipid rafts. The same findings were obtained by mutation of the acylation sites of signaling molecules, by prolonged culture of Jurkat T cells in the presence of palmitate and myristate analogs, or by disrupting lipid rafts with methyl-ß-cyclodextrin. In contrast to these agents, DPPE does not affect the integrity and protein composition of lipid rafts in resting T cells. However, it strongly inhibits the activation-induced recruitment of palmitoylated signaling molecules to lipid rafts and thus blocks antigen-specific T cell activation. DPPE acts rapidly at low concentration and therefore is an attractive new immunomodulatory agent.
FOOTNOTES
1 To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.00-0841fje ; to cite this
article, use FASEB J. (May 18, 2001) 10.1096/fj.00-0841fje ![]()
2 D.F.L. and M.-A.D. contributed equally to this work. ![]()
This article has been cited by other articles:
![]() |
J.-M. Segura, P. Guillaume, S. Mark, D. Dojcinovic, A. Johannsen, G. Bosshard, G. Angelov, D. F. Legler, H. Vogel, and I. F. Luescher Increased Mobility of Major Histocompatibility Complex I-Peptide Complexes Decreases the Sensitivity of Antigen Recognition J. Biol. Chem., August 29, 2008; 283(35): 24254 - 24263. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. J. Fawcett and U. Lorenz Localization of Src Homology 2 Domain-Containing Phosphatase 1 (SHP-1) to Lipid Rafts in T Lymphocytes: Functional Implications and a Role for the SHP-1 Carboxyl Terminus J. Immunol., March 1, 2005; 174(5): 2849 - 2859. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Doucey, D. F. Legler, M. Faroudi, N. Boucheron, P. Baumgaertner, D. Naeher, M. Cebecauer, D. Hudrisier, C. Ruegg, E. Palmer, et al. The {beta}1 and {beta}3 Integrins Promote T Cell Receptor-mediated Cytotoxic T Lymphocyte Activation J. Biol. Chem., July 11, 2003; 278(29): 26983 - 26991. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Guillaume, D. F. Legler, N. Boucheron, M.-A. Doucey, J.-C. Cerottini, and I. F. Luescher Soluble Major Histocompatibility Complex-Peptide Octamers with Impaired CD8 Binding Selectively Induce Fas-dependent Apoptosis J. Biol. Chem., February 7, 2003; 278(7): 4500 - 4509. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |